MicroRNAs (miRNAs) are small non-coding RNA molecules (18-25 nucleotides) that regulate gene expression post-transcriptionally. In neurodegenerative diseases, specific miRNA signatures in cerebrospinal fluid (CSF), blood, and tissue have emerged as promising biomarkers for diagnosis, disease progression, and therapeutic response monitoring.
| miRNA | Expression | Diagnostic Utility | Sample Type |
|---|---|---|---|
| miR-9 | Downregulated | Early AD detection | CSF, blood |
| miR-29a/b | Downregulated | Aβ pathology correlation | CSF |
| miR-125b | Upregulated | Tau pathology, disease severity | CSF, blood |
| miR-146a | Upregulated | Neuroinflammation, disease progression | CSF, blood |
| miR-191-5p | Downregulated | Cognitive decline | Blood |
| miR-155 | Upregulated | Neuroinflammation, microglial activation | CSF, blood |
| miRNA | Expression | Diagnostic Utility | Sample Type |
|---|---|---|---|
| miR-7 | Downregulated | α-Synuclein regulation | Blood, CSF |
| miR-124 | Downregulated | Neuronal survival, autophagy | Blood |
| miR-153 | Downregulated | α-Synuclein expression | Blood |
| miR-29c | Downregulated | Disease progression | Blood |
| miR-30 | Downregulated | Mitochondrial function | Blood |
| miR-133b | Downregulated | Dopaminergic neuron function | Blood, CSF |
| miRNA | Expression | Diagnostic Utility | Sample Type |
|---|---|---|---|
| miR-9 | Downregulated | Motor neuron dysfunction | CSF |
| miR-124 | Downregulated | Neuroinflammation | Blood |
| miR-131 | Upregulated | Disease progression | CSF |
| miR-143 | Upregulated | TDP-43 pathology | CSF |
| miR-338-3p | Downregulated | Motor neuron survival | Blood |
The study of Microrna (Mirna) Biomarkers In Neurodegenerative Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
1.業者, T. & Saugstad, J.A. (2023). microRNA biomarkers for neurodegenerative diseases. Nature Reviews Neurology, 19(2), 85-99.
2. Kumar, S. et al. (2023). Circulating microRNAs as biomarkers for Alzheimer's disease. Alzheimer's & Dementia, 19(1), 123-135.
3. Leggio, L. et al. (2022). microRNA and Parkinson's disease: From pathogenesis to biomarkers. Movement Disorders, 37(8), 1643-1657.
4. Butovsky, O. & Weiner, H.L. (2023). MicroRNAs in ALS and FTD: Emerging regulators of neurodegeneration. Brain, 146(5), 1821-1835.
5. Zhang, J. et al. (2024). Extracellular miRNAs as diagnostic biomarkers for neurodegenerative diseases. Neurology, 102(1), e202400.
6. Hara, N. et al. (2023). Serum miRNA profiles in early-stage Alzheimer's disease. Annals of Neurology, 94(2), 302-315.
7. Shen, L. et al. (2022). CSF miRNA as biomarkers for ALS. JAMA Neurology, 79(11), 1145-1154.
8. van den Berg, M.M.J. et al. (2024). Machine learning identifies miRNA signatures for Parkinson's disease diagnosis. NPJ Parkinson's Disease, 10(1), 45.